JF
LABP

Jump Financial’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Jump Financial’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,520
Closed -$73K – 2035
2021
Q4 		$73K Buy
+1,520
New +$160K ﹤0.01% 1266

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jump Financial's LABP Position: Q1 2022 in Review

Jump Financial sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q1 2022, closing a stake of 1,520 shares — an estimated $73K sold.

Jump Financial first reported a position in LABP in Q4 2021 and held it in 1 quarter. The position peaked at $73K in Q4 2021. 45 funds tracked by Wall St. Rank hold LABP as of Q1 2022.

  • Jump Financial reported no remaining Landos Biopharma, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Jump Financial sold 1,520 Landos Biopharma, Inc. Common Stock shares in Q1 2022, an estimated $73K.
  • Jump Financial first reported a position in Landos Biopharma, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Jump Financial's Landos Biopharma, Inc. Common Stock position peaked at $73K in Q4 2021.
  • 45 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q1 2022.

Based on Jump Financial's 13F filing for Q1 2022, filed 12 May 2022.